MaryBToddDO

PubMed

• Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of ...
  Fukasawa, S.,Suzuki, H.,Kawaguchi, K.,Noguchi, H.,Enjo, K.,Tran, N.,Todd, M.,Fizazi, K.,Matsubara, N.> ;Jpn. J. Clin. Oncol.. 2018 Oct 30
• 107 citations
  Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-na...
  Kim N. Chi, Andrew Protheroe, Alfredo Rodríguez-Antolín, Gaetano Facchini, Henrik Suttman, Nobuaki Matsubara, Zhangqun Ye, Bhumsuk Keam, Ronaldo Damião, Tracy Li, Kell...> ;The Lancet. Oncology. 2018 Feb 1
• 15 citations
  Impact of subsequent metastases on costs and medical resource use for prostate cancer patients initially diagnosed with localized disease
  Tracy Li, Neal D. Shore, Maneesha Mehra, Mary B. Todd, Ryan Saadi, Gaetan Leblay, Jyoti Aggarwal, Robert I. Griffiths> ;Cancer. 2017 Sep 15
• 31 citations
  Clinical Outcomes from Androgen Signaling–directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Pro...
  Matthew R. Smith, Fred Saad, Dana E. Rathkopf, Peter F.A. Mulders, Johann S. de Bono, Eric J. Small, Neal D. Shore, Karim Fizazi, Thian Kheoh, Jinhui Li, Peter De Porr...> ;European Urology. 2017 Jul 1
• 1304 citations
  Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
  Karim Fizazi, Nam Phuong Tran, Luis Fein, Nobuaki Matsubara, Alfredo Rodríguez-Antolín, Boris Alekseev, Mustafa Ozguroglu, Dingwei Ye, Susan Feyerabend, Andrew Prother...> ;The New England Journal of Medicine. 2017 Jun 4
• 9 citations
  Disease and Treatment Characteristics of Men Diagnosed With Metastatic Hormone-Sensitive Prostate Cancer in Real Life: Analysis From a Commercial Claims Database.
  Thomas W. Flaig, Ravi Potluri, Yvette Ng, Mary B. Todd, Maneesha Mehra, Celestia S. Higano> ;Clinical Genitourinary Cancer. 2017 Apr 1
• 60 citations
  Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
  Johann S. de Bono, Matthew R. Smith, Fred Saad, Dana E. Rathkopf, Peter F.A. Mulders, Eric J. Small, Neal D. Shore, Karim Fizazi, Peter De Porre, Thian Kheoh, Jinhui L...> ;European Urology. 2017 Apr 1
• 21 citations
  Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castr...
  Karim Fizazi, Kim N. Chi, Johann S. de Bono, Leonard G. Gomella, Kurt Miller, Dana E. Rathkopf, Charles J. Ryan, Howard I. Scher, Neal D. Shore, Peter De Porre, Anil L...> ;European Urology. 2016 Sep 1
• 9 citations
  Repeated measures analysis of patient-reported outcomes in prostate cancer after abiraterone acetate.
  David Cella, Susan Li, Tracy Li, Thian Kheoh, Mary B. Todd, Ethan Basch> ;The Journal of Community and Supportive Oncology. 2016 Apr 1
• 34 citations
  Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis o...
  Karim Fizazi, Thomas W. Flaig, Michael Stöckle, Howard I. Scher, J.S. de Bono, Dana E. Rathkopf, Charles J. Ryan, Thian Kheoh, Jinhui Li, Mary B. Todd, Thomas W. Griff...> ;Annals of Oncology. 2016 Apr 1
• 49 citations
  Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data.
  Thomas W. Flaig, Ravi Potluri, Yvette Ng, Mary B. Todd, Maneesha Mehra> ;Cancer Medicine. 2016 Feb 1
• 157 citations
  Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model
  Howard I. Scher, Kirk Solo, Jason Valant, Mary B. Todd, Maneesha Mehra> ;Plos One. 2015 Oct 13
• 192 citations
  Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (C...
  Dana E. Rathkopf, Matthew R. Smith, Johann S. de Bono, Christopher J. Logothetis, Neal D. Shore, Paul de Souza, Karim Fizazi, Peter F.A. Mulders, Paul N. Mainwaring, J...> ;European Urology. 2014 Nov 1
• 38 citations
  Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, earl...
  Cora N. Sternberg, Daniel Castellano, Gedske Daugaard, Lajos Géczi, Sebastien J. Hotte, Paul N. Mainwaring, Fred Saad, Ciro Souza, Miah H Tay, Jose Manuel Garrido, Luc...> ;The Lancet. Oncology. 2014 Oct 1
• 8 citations
  Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-Type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining wit...
  David William End, Arturo Molina, Mary B. Todd, Michael Meyers> ;Cancer Research. 2013 May 1
• 10 citations
  Fast and Flawed or Scientifically Sound: The Argument for Administering Oral Oncology Drugs During Fasting
  Mary B. Todd, Michael L. Meyers, Robert Charnas, Milin Acharya, Arturo Molina> ;Journal of Clinical Oncology. 2012 Mar 10
• Anti-tumor activity of partially HLA-matched irradiated blood mononuclear cells in patients with advanced malignancies.
  Strair R, Gharibo M, Taber Bs K, Kuriyan M, Dipaola R, Stein M, Todd M, Rubin A, Lattime E, Medina D> ;J. Clin. Oncol.. 2006-06-20
• Pre-treatment PSA doubling time (PSADT) predicts biochemical response to chemotherapy in patients with androgen sensitive PSA progression after local therapy.
  Mehta A, Stein M, Goodin S, Yao S, Shih J, Todd M, Dipaola RS> ;J. Clin. Oncol.. 2006-06-20
• Variation in local treatment of prostate cancer by hospital within New Jersey.
  Blom TR, Somer RA, Shih W, Sarno M, McNally D, Todd M, Yao S, Lu-Yao G, Dipaola R, Stein MN> ;J. Clin. Oncol.. 2006-06-20
• Phase I study of intravesical recombinant fowlpox-GM-CSF (rF-GMCSF) and/or recombinant Fowlpox-TRICOM (rF-TRICOM) in patients with advanced bladder cancer.
  Lattime EC, Weiss RE, Stein MN, Wojtowicz M, Todd MB, Morton RA, Hwang J, Bancila E, Ben-Menachem T, Dipaola RS> ;J. Clin. Oncol.. 2005-06-01
• A completed phase I trial of 13-cis retinoic acid, alpha interferon, docetaxel, and estramustine (R.I.T.E.) for the treatment of hormone refractory prostate cancer (HR...
  Stein MN, Todd MB, Morton RA, Doyle-Lindrud S, Goodin S, Shah A, Shih W, Garikapaty V, Dvorzhinski D, Dipaola RS> ;J. Clin. Oncol.. 2005-06-01
• 23 citations
  Effect of Docetaxel in Patients With Hormone-Dependent Prostate-Specific Antigen Progression After Local Therapy for Prostate Cancer
  Susan Goodin, Patrick J. Medina, Terry Capanna, Weichung Joe Shih, Sybil Abraham, Jessica Winnie, S. Doyle-Lindrud, Mary B. Todd, Robert S. DiPaola> ;Journal of Clinical Oncology. 2005 May 20
• 14 citations
  A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer.
  Susan Goodin, Kamakshi V. Rao, Michael P. Kane, Nisha Dave, Terry Capanna, S. Doyle-Lindrud, Elizabeth Engle, Lixian Jin, Mary B. Todd, Robert S. DiPaola> ;Cancer Chemotherapy and Pharmacology. 2005 Apr 19
• 44 citations
  A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer.
  Donald S. Kaufman, Michael A. Carducci, Timothy M. Kuzel, Mary B. Todd, William Oh, Matthew R. Smith, Zhishen Ye, Steven J. Nicol, Walter M. Stadler> ;Urologic Oncology. 2004 Sep 1
• Phase I dose-escalation trial investigating the safety and tolerability of EPO906 plus estramustine in patients with advanced cancer.
  Wojtowicz M, Rothermel JD, Anderson J, Todd M, Rubin EH, Dipaola RS> ;J. Clin. Oncol.. 2004-07-15
• Join now to see all